Outsmarting drugs
Let’s start with the basics: antibiotic resistance happens when bacteria evolve to survive the drugs meant to kill them. It’s one of the biggest threats to global heath. Infections that used to be easily treatable are now becoming stubborn — or even untreatable.
The WHO analyzed more than 23 million bacterial infections in over 100 countries. The finding? One in six infections worldwide no longer respond to standard antibiotics. And between 2018 and 2023, increasing resistance to bacterial drugs was observed in more than 40% of the treatments that WHO tracks.
Some regions are hit harder than others. In Southeast Asia and the Eastern Mediterranean, about one in three infections are resistant. In Africa, it’s closer to one in five. The WHO says resistance tends to spike where health systems are weaker.
Overuse is a major culprit — both in humans and animals. Doctors sometimes prescribe antibiotics unnecessarily, and patients self-medicate. In agriculture, antibiotics are used to boost livestock growth and prevent disease, even when not needed.
The toll is staggering. In 2019, antimicrobial resistance caused 1.27 million deaths and was linked to nearly 5 million more. Without global action, the WHO warns we could see up to $3 trillion in annual gross domestic product losses by 2030.
The pace of resistance “is outstripping advances in modern medicine,” said WHO Director-General Tedros Adhanom Ghebreyesus. “We must use antibiotics responsibly, and make sure everyone has access to the right medicines, quality-assured diagnostics, and vaccines.”
Antibiotic resistance is part of a broader issue: antimicrobial resistance (AMR), which also includes resistance to antivirals and antifungals. The WHO launched a global AMR surveillance system in 2015, and participation has quadrupled. But some key countries — like China — still aren’t sharing data.
“The findings are alarming but not surprising,” said Anita Williams, an epidemiologist at the University of Western Australia, “It is vital that we continue to improve surveillance efforts and fund epidemiological research into the drivers of antimicrobial resistance.” — Karoline Kan
| |
|
Enjoyed this article? Sign up for our newsletter to receive regular insights and stay connected.